BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 32234906)

  • 1. EZH2 and MMSET Were Identified as Potentially Useful Therapeutic Targets in Metaplastic Breast Carcinoma.
    Nakayama H; Kawachi K; Suganuma N; Yoshida T; Yamashita T; Yamanaka T; Matsubara Y; Kohagura K; Toda S; Nakamura Y; Miyagi Y; Rino Y; Masuda M
    Anticancer Res; 2020 Apr; 40(4):2133-2139. PubMed ID: 32234906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations of
    Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
    Edenfield J; Schammel C; Collins J; Schammel D; Edenfield WJ
    Clin Breast Cancer; 2017 Feb; 17(1):e1-e10. PubMed ID: 27568101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
    Hussein YR; Sood AK; Bandyopadhyay S; Albashiti B; Semaan A; Nahleh Z; Roh J; Han HD; Lopez-Berestein G; Ali-Fehmi R
    Hum Pathol; 2012 Oct; 43(10):1638-44. PubMed ID: 22436627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma.
    Cimino-Mathews A; Verma S; Figueroa-Magalhaes MC; Jeter SC; Zhang Z; Argani P; Stearns V; Connolly RM
    Am J Clin Pathol; 2016 Mar; 145(3):365-72. PubMed ID: 27124919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma.
    Yang S; Zhang Y; Meng F; Liu Y; Xia B; Xiao M; Xu Y; Ning X; Li H; Lou G
    Biomarkers; 2013 May; 18(3):257-63. PubMed ID: 23566000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
    Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
    Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
    Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
    El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
    Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features of metaplastic breast carcinoma.
    Hasdemir OA; Tokgöz S; Köybaşıoğlu F; Karabacak H; Yücesoy C; İmamoğlu Gİ
    Adv Clin Exp Med; 2018 Apr; 27(4):509-513. PubMed ID: 29558027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.
    Kumari K; Das B; Adhya AK; Rath AK; Mishra SK
    Sci Rep; 2019 Feb; 9(1):1974. PubMed ID: 30760814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity.
    Lim KH; Oh DY; Chie EK; Han W; Im SA; Kim TY; Park IA; Noh DY; Ha SW; Bang YJ
    Jpn J Clin Oncol; 2010 Feb; 40(2):112-8. PubMed ID: 19887523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique characteristics and failure patterns of metaplastic breast cancer in contrast to invasive ductal carcinoma: a retrospective multicenter case-control study (KROG 13-07).
    Yu JI; Choi DH; Huh SJ; Ahn SJ; Lee JS; Shin KH; Kwon Y; Kim YB; Suh CO; Kim JH; Cho J; Kim IA; Lee JH; Park W
    Clin Breast Cancer; 2015 Apr; 15(2):e105-15. PubMed ID: 25459069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.
    Hudlebusch HR; Santoni-Rugiu E; Simon R; Ralfkiær E; Rossing HH; Johansen JV; Jørgensen M; Sauter G; Helin K
    Clin Cancer Res; 2011 May; 17(9):2919-33. PubMed ID: 21385930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and treatment outcomes of metaplastic breast carcinoma: Single tertiary care center experience in Pakistan.
    Samoon Z; Beg M; Idress R; Jabbar AA
    Indian J Cancer; 2019; 56(2):124-129. PubMed ID: 31062730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.